Learn more

UNIV TOLEDO

Overview
  • Total Patents
    710
  • GoodIP Patent Rank
    5,809
  • Filing trend
    ⇩ 36.0%
About

UNIV TOLEDO has a total of 710 patent applications. It decreased the IP activity by 36.0%. Its first patent ever was published in 1969. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and organic fine chemistry are UNIV WENZHOU MEDICAL, UNIV OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION and UNIV MICHIGAN REGENTS.

Patent filings per year

Chart showing UNIV TOLEDOs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Goel Vijay K 73
#2 Agarwal Anand K 53
#3 Varanasi Sasidhar 47
#4 Erhardt Paul W 35
#5 Shapiro Joseph I 32
#6 Durant Graham J 29
#7 Selman Steven H 27
#8 Bhaduri Sarit B 27
#9 Viamajala Sridhar 25
#10 Zhou Huan 24

Latest patents

Publication Filing date Title
US2021104686A1 Materials and Methods to Improve the Stability of Metal Halide Perovskites
WO2021046502A2 Kits and methods for testing for lung cancer risks
US2021023240A1 Thermoresponsive Injectable Microparticles-Gel Composites with Low Dose of Recombinant BMP-9 and VEGF for Bone Repair
US2020369603A1 Development of a Cofilin Inhibitor for the Treatment of Hemorrhagic Brain Injury-Induced Neuroinflammation
US2020343403A1 PERC-like Contact to CdTe Solar Cells
US2020324250A1 Assembly of Charge Mosaic Membranes from Ionic Polymers
US2020289440A1 Use of Formin Agonists in Overcoming Brain Tumor Radio- and Chemo-resistance by Targeting Tumor Microtubes
US2020271603A1 Sensor for detection and measurement of ice, snow and liquid water content (lwc) and methods of using same
US2020276739A1 Microcellular materials with stress-activated pores exhibiting opto-mechanical properties and their use as sensors
WO2020176289A1 Pegylated bilirubin for the treatment of hyperlipidemia, obesity, fatty liver disease cardiovascular diseases and type ii diabetes
WO2020172086A1 Targeting lasp1, eif4a1, eif4b, and cxc4 with modulators and combinations thereof for cancer therapy
US2020253532A1 Telestroke Eye Examination Accessory
US2020172526A1 Furoxans as therapies for neurodegenerative disorders
WO2020102623A1 Materials and methods for the prevention of rheumatoid arthritis
WO2020097546A1 Immunosuppressive antigen-specific chimeric antigen receptor treg cells for prevention and/or treatment of autoimmune and alloimmune disorders
US2020185931A1 Bilevel equalizer for battery cell charge management
US2020119379A1 Crosslinked Membrane for Anion Exchange Applications
US2020102410A1 Pyrrole-Based Polymers for Metal Extraction, Analysis, and Removal
US2020072264A1 Materials and methods for joining metal sheets
US2020037586A1 Spontaneous Autoimmune Diabetes in Humanized Mice Carrying Human Type 1 Diabetes Susceptibility and Uses Therefor